This meta-analysis assessed the prevalence of allergy, eosinophilia, and hyper-IgE in patients with IgG4-related disease (IgG4-RD). The analysis included 8233 patients for allergy, 4376 for eosinophilia, and 2353 for hyper-IgE. The pooled proportion of patients with allergy was 0.44 (95% CI 0.39-0.49; p<0.01), eosinophilia was 0.22 (95% CI 0.18-0.26; p<0.01), and hyper-IgE was 0.73 (95% CI 0.63-0.83; p<0.01).
The study does not establish causality and reports only associations. No comparative data against the general population were provided, limiting the ability to determine if these proportions are elevated relative to expected background rates. Limitations were not reported in the source, and no information on study design, setting, or funding was available.
Clinicians should recognize that allergy, eosinophilia, and hyper-IgE are common in IgG4-RD patients, but these findings should not be interpreted as causal. The absence of a comparator group means the clinical significance of these proportions remains uncertain. Further research with appropriate controls is needed.
View Original Abstract ↓
BACKGROUND: IgG4-related disease (IgG4-RD) is an immune-mediated condition characterized by multi-organ involvement. Substantial evidence suggests a close link between allergy and IgG4-RD, supported by the high prevalence of allergic comorbidities in patients and shared immunological features such as eosinophilia and elevated serum IgE. However, the precise mechanistic connections and potential causal relationship between allergy and IgG4-RD remain unclear. This study aimed to systematically quantify the proportion of IgG4-RD patients presenting with allergy, eosinophilia, and hyper-IgE.
METHODS: A comprehensive literature search of the PubMed, Web of Science, EMBASE, and the Cochrane Library was conducted up to August 7, 2025. Studies meeting the inclusion criteria were reviewed. Meta-analysis was performed using both random- and fixed-effects models.
RESULTS: The search identified 1884 studies, of which 32 were included in the analysis. Among these, 30 studies contributed to the allergy analysis, 15 to eosinophilia, and 9 to hyper-IgE. The meta-analysis showed that the pooled proportion of IgG4-RD patients with allergy was 0.44 (95% CI, 0.39, 0.49; p < 0.01; n = 8233). The pooled proportion with eosinophilia was 0.22 (95% CI, 0.18, 0.26; p < 0.01; n = 4376), and with hyper-IgE was 0.73 (95% CI, 0.63, 0.83; p < 0.01; n = 2353).
CONCLUSIONS: A notable proportion of IgG4-RD patients exhibit allergy, eosinophilia, and hyper-IgE. The frequent co-occurrence of these features highlights the need to investigate the underlying mechanisms, clarify the causal relationship between allergy and IgG4-RD, and provide further insights for both mechanistic research and clinical management of IgG4-RD, especially through well-controlled comparative studies to establish whether these features are truly more prevalent in IgG4-RD than in the general population or other conditions.